These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24170546)

  • 41. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Huang Y; Yu H; Lei H; Xie C; Zhong Y
    Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
    Sato K; Suda K; Shimizu S; Sakai K; Mizuuchi H; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    PLoS One; 2016; 11(4):e0154186. PubMed ID: 27100677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of leptin in colorectal adenocarcinoma showed significant different survival patterns associated with tumor size, lymphovascular invasion, distant metastasis, local recurrence, and relapse of disease in the western province of Saudi Arabia.
    Al-Maghrabi JA; Qureshi IA; Khabaz MN
    Medicine (Baltimore); 2018 Aug; 97(34):e12052. PubMed ID: 30142858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TAZ expression as a prognostic indicator in colorectal cancer.
    Yuen HF; McCrudden CM; Huang YH; Tham JM; Zhang X; Zeng Q; Zhang SD; Hong W
    PLoS One; 2013; 8(1):e54211. PubMed ID: 23372686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Qigesan inhibits esophageal cancer cell invasion and migration by inhibiting Gas6/Axl-induced epithelial-mesenchymal transition.
    Kong L; Lu X; Chen X; Wu Y; Zhang Y; Shi H; Li J
    Aging (Albany NY); 2020 May; 12(10):9714-9725. PubMed ID: 32432570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway.
    Xu J; Jia L; Ma H; Li Y; Ma Z; Zhao Y
    Tumour Biol; 2014 Apr; 35(4):3809-17. PubMed ID: 24347489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency.
    Rocha-Brito KJP; Fonseca EMB; Oliveira BGF; Fátima Â; Ferreira-Halder CV
    Bioorg Chem; 2020 Jul; 100():103881. PubMed ID: 32388429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.
    Chatla C; Jhala NC; Katkoori VR; Alexander D; Meleth S; Grizzle WE; Manne U
    Cancer Biomark; 2005; 1(4-5):241-50. PubMed ID: 17192048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
    Nam RK; Benatar T; Wallis CJD; Kobylecky E; Amemiya Y; Sherman C; Seth A
    Prostate; 2019 Sep; 79(12):1422-1438. PubMed ID: 31269290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
    Jiang Z; Hou Z; Liu W; Yu Z; Liang Z; Chen S
    Bioengineered; 2022 Jan; 13(1):810-823. PubMed ID: 34974791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
    Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
    Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma.
    Cichoń MA; Szentpetery Z; Caley MP; Papadakis ES; Mackenzie IC; Brennan CH; O'Toole EA
    Oncogene; 2014 Aug; 33(32):4185-92. PubMed ID: 24056961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.